---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-194994"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:30:46.165802+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical gets Nasdaq MVLS deficiency notice; stockholders approve reverse stock split

## Summary
- Received Nasdaq notice on Aug 28, 2025 for non-compliance with $50M MVLS requirement for continued listing on Global Market.
- Company has 180 days until Feb 24, 2026 to regain compliance; may consider transfer to Nasdaq Capital Market.
- At special meeting Aug 29, 2025, stockholders approved reverse stock split in range of 1-for-5 to 1-for-15 to address bid price deficiency.
- Reverse stock split approved with 46.5M for, 2.2M against, 459k abstained out of 49.2M shares present.

## SEC filing metadata
- accession: 0001193125-25-194994
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000119312525194994/0001193125-25-194994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000119312525194994/clsd-20250828.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-194994
- JSON: https://secwatch.observer/filing/0001193125-25-194994.json
- Plain text: https://secwatch.observer/filing/0001193125-25-194994.txt

## Key facts
- Listing & Compliance Notices
  Clearside Biomedical, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(A)
  source text: August 28, 2025, Clearside Biomedical, Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common stock was not in compliance with the minimum Market Value of Listed Securities (“ MVLS ”) of $50,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “ MVLS Requirement ”). The notice has no present impact on the listing of the Company’s securities on the Nasdaq Global Market. Under Nasdaq Listing Rule 5810(c
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000119312525194994/0001193125-25-194994-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.